Response of ELA-A1 horses immunized with lipopeptide containing an equine infectious anemia virus ELA-A1-restricted CTL epitope to virus challenge

Vaccine

Volumn 21, Issue 5-6, 2003, Pages 491-506

  Ridgely, Sherritta L ^a   Zhang, Baoshan ^a   McGuire, Travis C ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Cytotoxic T lymphocyte epitopes; Equine infectious anemia; Lipopeptide immunization

Indexed keywords

EPITOPE; LIPOPEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CYTOTOXIC T LYMPHOCYTE; EQUINE INFECTIOUS ANEMIA VIRUS; FEVER; HAPLOTYPE; HORSE; IMMUNIZATION; INOCULATION; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTOPENIA; VIREMIA; VIRUS LOAD;

AMINO ACID SUBSTITUTION; ANIMALS; CELLS, CULTURED; EPITOPES; EQUINE INFECTIOUS ANEMIA; HAPLOTYPES; HORSES; IMMUNIZATION; INFECTIOUS ANEMIA VIRUS, EQUINE; LIPOPROTEINS; PLATELET COUNT; RNA, VIRAL; T-LYMPHOCYTES, CYTOTOXIC; THROMBOCYTOPENIA;

EID: 0037449492     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00474-7     Document Type: Article

References (68)

1. Koup R.A., Safrit J.T., Cao Y.et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:1994;4650-4655.
2. Buseyne F., Riviere Y. HIV-specific CD8+ T-cell immune responses and viral replication. AIDS. 7(Suppl. 2):1993;S81-S85.
3. Borrow P., Lewicki H., Hahn B.H., Shaw G.M., Oldstone M.B. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68:1994;6103-6110.
4. Buseyne F., Burgard M., Teglas J.P.et al. Early HIV-specific cytotoxic T lymphocytes and disease progression in children born to HIV-infected mothers. AIDS Res. Hum. Retroviruses. 14:1998;1435-1444.
5. Rinaldo C.R. Jr., Huang X.L., Fan Z.et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J. Virol. 69:1995;5838-5842.
6. Pu R., Omori M., Okada S.et al. MHC-restricted protection of cats against FIV infection by adoptive transfer of immune cells from FIV-vaccinated donors. Cell Immunol. 198:1999;30-43.
7. Flynn J.N., Hosie M.J., Rigby M.A.et al. Factors influencing cellular immune responses to feline immunodeficiency virus induced by DNA vaccination. Vaccine. 18:2000;1118-1132.
8. Hosie M.J., Flynn J.N., Rigby M.A.et al. DNA vaccination affords significant protection against feline immunodeficiency virus infection without inducing detectable antiviral antibodies. J. Virol. 72:1998;7310-7319.
9. Wilson L.A., Murphey-Corb M., Martin L.N., Harrison R.M., Ratterree M.S., Bohm R.P. Identification of SIV Env-specific CTL in the jejunal mucosa in vaginally exposed, seronegative rhesus macaques (Macaca mulatta). J. Med. Primatol. 29:2000;173-181.
10. Letvin N.L., Schmitz J.E., Jordan H.L.et al. Cytotoxic T lymphocytes specific for the simian immunodeficiency virus. Immunol. Rev. 170:1999;127-134.
11. Metzner K.J., Jin X., Lee F.V.et al. Effects of in vivo CD8(+) T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J. Exp. Med. 191:2000;1921-1931.
12. Jin X., Bauer D.E., Tuttleton S.E.et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189:1999;991-998.
13. Kannagi M., Chalifoux L.V., Lord C.I., Letvin N.L. Suppression of simian immunodeficiency virus replication in vitro by CD8+ lymphocytes. J. Immunol. 140:1988;2237-2242.
14. Yasutomi Y., Koenig S., Woods R.M. A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge. J. Virol. 69:1995;2279-2284.
15. McGuire T.C., Crawford T.B., Henson J.B. Immunofluorescent localization of equine infectious anemia virus in tissue. Am. J. Pathol. 62:1971;283-294.
16. Maury W., Oaks J.L., Bradley S. Equine endothelial cells support productive infection of equine infectious anemia virus. J. Virol. 72:1998;9291-9297.
17. Oaks J.L., Ulibarri C., Crawford T.B. Endothelial cell infection in vivo by equine infectious anaemia virus. J. Gen. Virol. 80:1999;2393-2397.
18. Perryman L.E., O'Rourke K.I., McGuire T.C. Immune responses are required to terminate viremia in equine infectious anemia lentivirus infection. J. Virol. 62:1988;3073-3076.
19. O'Rourke K., Perryman L.E., McGuire T.C. Antiviral, anti-glycoprotein and neutralizing antibodies in foals with equine infectious anaemia virus. J. Gen. Virol. 69:1988;667-674.
20. Montelaro R.C., Ball J.M., Issel C.J. Characterization of EIAV immunogenicity during persistent infections: Humoral responses and antigen targets. Dev. Biol. Stand. 72:1990;19-30.
21. Issel C.J., Horohov D.W., Lea D.F.et al. Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus. J. Virol. 66:1992;3398-3408.
22. Sellon D.C., Fuller F.J., McGuire T.C. The immunopathogenesis of equine infectious anemia virus. Virus Res. 32:1994;111-138.
23. McGuire T.C., Tumas D.B., Byrne K.M.et al. Major histocompatibility complex-restricted CD8+ cytotoxic T lymphocytes from horses with equine infectious anemia virus recognize Env and Gag/PR proteins. J. Virol. 68:1994;1459-1467.
24. Hammond S.A., Cook S.J., Lichtenstein D.L., Issel C.J., Montelaro R.C. Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process. J. Virol. 71:1997;3840-3852.
25. Zhang W., Lonning S.M., McGuire T.C. Gag protein epitopes recognized by ELA-A-restricted cytotoxic T lymphocytes from horses with long-term equine infectious anemia virus infection. J. Virol. 72:1998;9612-9620.
26. Mortara L., Letourneur F., Gras-Masse H., Venet A., Guillet J.G., Bourgault-Villada I. Selection of virus variants and emergence of virus escape mutants after immunization with an epitope vaccine. J. Virol. 72:1998;1403-1410.
27. Mortara L., Gras-Masse H., Rommens C., Venet A., Guillet J.G., Bourgault-Villada I. Type 1 CD4(+) T-cell help is required for induction of antipeptide multispecific cytotoxic T lymphocytes by a lipopeptidic vaccine in rhesus macaques. J. Virol. 73:1999;4447-4451.
28. Bourgault I., Chirat F., Tartar A., Levy J.P., Guillet J.G., Venet A. Simian immunodeficiency virus as a model for vaccination against HIV. Induction in rhesus macaques of GAG- or NEF-specific cytotoxic T lymphocytes by lipopeptides. J. Immunol. 152:1994;2530-2537.
29. BenMohamed L., Gras-Masse H., Tartar A.et al. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. Eur. J. Immunol. 27:1997;1242-1253.
30. Livingston B.D., Crimi C., Grey H.et al. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. J. Immunol. 159:1997;1383-1392.
31. Steller M.A., Gurski K.J., Murakami M.et al. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin. Cancer Res. 4:1998;2103-2109.
32. Vitiello A., Ishioka G., Grey H.M.et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J. Clin. Invest. 95:1995;341-349.
33. Shirai M., Chen M., Arichi T.et al. Use of intrinsic and extrinsic helper epitopes for in vivo induction of anti-hepatitis C virus cytotoxic T lymphocytes (CTL) with CTL epitope peptide vaccines. J. Infect. Dis. 173:1996;24-31.
34. Defoort J.P., Nardelli B., Huang W., Ho D.D., Tam J.P. Macromolecular assemblage in the design of a synthetic AIDS vaccine. Proc. Natl. Acad. Sci. U.S.A. 89:1992;3879-3883.
35. Schild H., Deres K., Wiesmuller K.H., Jung G., Rammensee H.G. Efficiency of peptides and lipopeptides for in vivo priming of virus-specific cytotoxic T cells. Eur. J. Immunol. 21:1991;2649-2654.
36. Borges E., Wiesmuller K.H., Jung G., Walden P. Efficacy of synthetic vaccines in the induction of cytotoxic T lymphocytes. Comparison of the costimulating support provided by helper T cells and lipoamino acid. J. Immunol. Methods. 173:1994;253-263.
37. Deres K., Schild H., Wiesmuller K.H., Jung G., Rammensee H.G. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature. 342:1989;561-564.
38. Nardelli B., Tam J.P. Cellular immune responses induced by in vivo priming with a lipid-conjugated multimeric antigen peptide. Immunology. 79:1993;355-361.
39. Defoort J.P., Nardelli B., Huang W., Tam J.P. A rational design of synthetic peptide vaccine with a built-in adjuvant. A modular approach for unambiguity. Int. J. Pept. Protein Res. 40:1992;214-221.
40. Mora A.L., Tam J.P. Controlled lipidation and encapsulation of peptides as a useful approach to mucosal immunizations. J. Immunol. 161:1998;3616-3623.
41. Hioe C.E., Qiu H., Chend P.D. Comparison of adjuvant formulation for cytotoxic T cell induction using synthetic peptides. Cell. 54:1996;777-785.
42. Andrieu M., Loing E., Desoutter J.F. Endocytosis of an HIV-derived lipopeptide into human dendritic cells followed by class I-restricted CD8(+) T lymphocyte activation. Eur. J. Immunol. 30:2000;3256-3265.
43. Wolf B., Hauschildt S., Uhl B., Metzger J., Jung G., Bessler W.G. Localization of the cell activator lipopeptide in bone marrow-derived macrophages by electron energy loss spectroscopy (EELS). Immunol. Lett. 20:1989;121-126.
44. Hertz C.J., Kiertscher S.M., Godowski P.J.et al. Microbial lipopeptides stimulate dendritic cell maturation via toll-like receptor 2. J. Immunol. 166:2001;2444-2450.
45. Muller M.R., Pfannes S.D., Ayoub M., Hoffmann P., Bessler W.G., Mittenbuhler K. Immunostimulation by the synthetic lipopeptide P3CSK4: TLR4-independent activation of the ERK1/2 signal transduction pathway in macrophages. Immunology. 103:2001;49-60.
46. Hoffmann P., Heinle S., Schade U.F.et al. Stimulation of human and murine adherent cells by bacterial lipoprotein and synthetic lipopeptide analogues. Immunobiology. 177:1988;158-170.
47. Hauschildt S., Hoffmann P., Beuscher H.U.et al. Activation of bone marrow-derived mouse macrophages by bacterial lipopeptide: Cytokine production, phagocytosis and Ia expression. Eur. J. Immunol. 20:1990;63-68.
48. van Gool S.W., Kasran A., Wallays G., de Boer M., Ceuppens J.L. Accessory signalling by B7-1 for T cell activation induced by anti-CD2: Evidence for IL-2-independent CTL generation and CsA-resistant cytokine production. Scand. J. Immunol. 41:1995;23-30.
49. Nagoya S., Greenberg P.D., Yee C.et al. Helper T cell-independent proliferation of CD8+ cytotoxic T lymphocytes transduced with an IL-1 receptor retrovirus. J. Immunol. 153:1994;1527-1535.
50. Ford H.R., Hoffman R.A., Wang S., Simmons R.L. Induction of cytotoxic T lymphocyte development from murine thymocytes by IL-1 and IL-6. J. Pediatr. Surg. 26:1991;397-400.
51. Ridgely S.R., McGuire T.C. Lipopeptide stimulation of MHC class I-restricted memory cytotoxic T lymphocytes from equine infectious anemia virus-infected horses. Vaccine. 20:2002;1809-1819.
52. Fields G.B., Noble R.L. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int. J. Pept. Protein Res. 35:1990;161-214.
53. Plowright PD, Rossdale PD, Wade JF, editors. The major histocompatibility complex of the horse. Newmarket: R&W Publications, 1991.
54. Bailey E. Population studies on the ELA system in American standardbred and thoroughbred mares. Anim. Blood Groups Biochem. Genet. 14:1983;201-211.
55. Bailey E. Identification and genetics of horse lymphocyte alloantigens. Immunogenetics. 11:1980;499-506.
56. Marti E, Szalai G, Antczak DF, Bailey E, Gerber H, Lazary S. The equine major histocompatibility complex. In: Schook LB, Lamont SJ, editors. The major histocompatibility complex region of domestic animal species. Boca Raton, FL: CRC Press, 1996. p. 245-68.
57. Bailey E, Marti E, Fraser DG, Antczak DF. Immunogenetics of the horse. In: Bowling AT, Ruvinsky A, editors. The genetics of the horse. New York: CABI, 2000. p. 123-55.
58. McGuire T.C., Zhang W., Hines M.T., Henney P.J., Byrne K.M. Frequency of memory cytotoxic T lymphocytes to equine infectious anemia virus proteins in blood from carrier horses. Virology. 238:1997;85-93.
59. McGuire T.C., Leib S.R., Lonning S.M., Zhang W., Byrne K.M., Mealey R.H. Equine infectious anaemia virus proteins with epitopes most frequently recognized by cytotoxic T lymphocytes from infected horses. J. Gen. Virol. 81:2000;2735-2739.
60. Siliciano R.F., Keegan A.D., Dintzis R.Z., Dintzis H.M., Shin H.S. The interaction of nominal antigen with T cell antigen receptors. I. Specific binding of multivalent nominal antigen to cytolytic T cell clones. J. Immunol. 135:1985;906-914.
61. Reed L.J., Muench H.A. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:1938;493-497.
62. Mendenhall W. Nonparametric statistics. In: Blodgett N, editor. Introduction to probability and statistics. Boston: Prindle, Weber & Schmidt, 1983. p. 604-43.
63. Ryder EF, Robakiewicz P. Statistics for the molecular biologist: Group comparisons. In: Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JM, editors. Current protocols in molecular biology. New York: Wiley, 1998. p. A.3I.1-22.
64. Wiedemann F., Link R., Pumpe K. Histopathological studies on the local reactions induced by complete Freund's adjuvant (CFA), bacterial lipopolysaccharide (LPS), and synthetic lipopeptide (P3C) conjugates. J. Pathol. 164:1991;265-271.
65. Lichtenstein D.L., Issel C.J., Montelaro R.C. Genomic quasispecies associated with the initiation of infection and disease in ponies experimentally infected with equine infectious anemia virus. J. Virol. 70:1996;3346-3354.
66. Livingston B.D., Crimi C., Fikes J., Chesnut R.W., Sidney J., Sette A. Immunization with the HBV core 18-27 epitope elicits CTL responses in humans expressing different HLA-A2 supertype molecules. Hum. Immunol. 60:1999;1013-1017.
67. Elliott S.L., Pye S., Le T.et al. Peptide based cytotoxic T-cell vaccines; delivery of multiple epitopes, help, memory and problems. Vaccine. 17:1999;2009-2019.
68. Huang W., Nardelli B., Tam J.P.et al. Lipophilic multiple antigen peptide system for peptide immunogen and synthetic vaccine. Mol. Immunol. 31:1994;1191-1199.